Precision BioSciences to Regain Programs After Prevail Team-Up Ends
By Dean Seal
Precision BioSciences expects to get three programs back from Prevail Therapeutics after a gene-editing collaboration between the two companies ended.
The advanced gene-editing company said Tuesday that it has exercised its option to regain rights for the programs after Prevail, a subsidiary of Eli Lilly, elected to conclude the collaboration that started up in January 2021.
The two companies advanced three programs from concept toward clinical candidates during that time, Chief Executive Michael Amoroso said.
Given the strong proof-of-concept data generated so far, Precision is looking into opportunities to develop the returned programs independently or in partnership with others, it said.
The return of the programs isn't expected to impact Precision's near-term clinical priorities, the company said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 16, 2024 17:07 ET (21:07 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now